Abstract
The resource utilization and cost of 51 episodes of febrile neutropenia in children with leukemia and lymphomas who were admitted to the Pediatric Oncology Institute (GRAAC) of the Federal University of São Paulo were analyzed. Patients aged 60 days to 21 years with confirmed diagnoses of acute myeloid leukemia, acute lymphoid leukemia, non-Hodgkin lymphoma, or Hodgkin´s disease who presented axillary temperature above 38°C at least once episode, or between 37.5° C and 38°C on three occasions during a 24-h period, neutrophil count below 500/mm3, or between 500/mm3 and 1,000/mm3 but expected to fall below 500/mm3 were included in the study. The patients' ages varied between 1 and 15.6 years, and 67% of the patients were male. The median cost per treated episode was US $ 2,660 (2,039). Hospitalization costs accounted for 62% of the total cost of the treatment, antibacterials accounting for 23% . Episodes in patients with documented infections had a higher median direct cost than episodes in patients with fever of unknown origin (P=0.018). There was a trend for a higher median direct cost in episodes among patients with a worse prognostic factor, such as type of underlying disease, presence of documented infection, and longer duration of neutropenia. This is the first study to evaluate the economics of febrile neutropenia episodes in Brazil, and serves as a basis for resource utilization and costs incurred in the treatment of such patients in this country.
Similar content being viewed by others
References
Agaoglu L, Devecioglu O, Karakas Z, et al (2001) Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 13:281–287
Ariffin H, Arasu A, Mahfuzah M, Ariffin WA, Chan LL, Lin HP (2001) Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. J Pediatr Child Health 37:38–43
Brasindice (2000) Pharmaceutical guide. Andrei, Brasília
Brazilian Medical Association (1966) List of medical procedures. Brazilian Medical Association, Brasília
Castagnola E, Paola D, Giacchino R, Rossi R, Viscoli C (1998) Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer 6:524–528
Dietrich ES, Patz E, Frank U, Daschner FD (1999) Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany. Infection 27:23–31
Dranitsaris G (1999) Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer. Pharmacoeconomics 16:343–353
Harbarth S, Beeler I, Viot M, Szucs TD (1999) Resource implications of febrile neutropenia in cancer patients—an international collaborative study. Support Care Cancer 7:343–346
Hughes WT, Armstrong D, Bodey GP, et al (1997) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 25:551–573
Kairos Pharmaceutical Journal (in Portuguese) (2000) issue 141
Leese B (1993) The costs of treating febrile neutropenia in six U.K. hospitals. Eur J Cancer 29 [A] S7:S15–S18
Leese B, Collin R, Clark DJ (1994) The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 6:233–239
Paladino JA, Fong DA, Forrest A, Ramphal R (2000) Cost effectiveness of cephalosporin monotherapy and aminoglycoside / ureidopenicillin combination therapy—for the treatment of febrile episodes in neutropenic patients. Pharmacoeconomics 18:369–381
Petrilli AS, Melaragno R, Barros KVT, et al (1993) Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease. Pediatr Infect Dis J 12:916–921
Torfs K (1997) Economic evaluation of cancer treatment strategies. Eur J Cancer 33 [S4]:S35–S39
Acknowledgements
This study was supported by the Pediatric Oncology Institute/GRAACC and by Bristol-Myers Squibb Brazil.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Costa, V.C., Ferraz, M.B., Petrilli, A.S. et al. Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas. Support Care Cancer 11, 356–361 (2003). https://doi.org/10.1007/s00520-002-0429-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-002-0429-1